A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates

Ongoing severe acute respiratory syndrome coronavirus–2 (SARS-CoV-2) vaccine development is focused on identifying stable, cost-effective, and accessible candidates for global use, specifically in low- and middle-income countries. Here, we report the efficacy of a rapidly scalable, novel yeast-expre...

Descripción completa

Detalles Bibliográficos
Autores principales: Pino, Maria, Abid, Talha, Pereira Ribeiro, Susan, Edara, Venkata Viswanadh, Floyd, Katharine, Smith, Justin C., Latif, Muhammad Bilal, Pacheco-Sanchez, Gabriela, Dutta, Debashis, Wang, Shelly, Gumber, Sanjeev, Kirejczyk, Shannon, Cohen, Joyce, Stammen, Rachelle L., Jean, Sherrie M., Wood, Jennifer S., Connor-Stroud, Fawn, Pollet, Jeroen, Chen, Wen-Hsiang, Wei, Junfei, Zhan, Bin, Lee, Jungsoon, Liu, Zhuyun, Strych, Ulrich, Shenvi, Neeta, Easley, Kirk, Weiskopf, Daniela, Sette, Alessandro, Pollara, Justin, Mielke, Dieter, Gao, Hongmei, Eisel, Nathan, LeBranche, Celia C., Shen, Xiaoying, Ferrari, Guido, Tomaras, Georgia D., Montefiori, David C., Sekaly, Rafick P., Vanderford, Thomas H., Tomai, Mark A., Fox, Christopher B., Suthar, Mehul S., Kozlowski, Pamela A., Hotez, Peter J., Paiardini, Mirko, Bottazzi, Maria Elena, Kasturi, Sudhir Pai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119307/
https://www.ncbi.nlm.nih.gov/pubmed/34266981
http://dx.doi.org/10.1126/sciimmunol.abh3634

Ejemplares similares

Ejemplares similares